FAP, May 12 / PRNewswire-FirstCall-Asianet /-- Hanyu Pharmaceutical announced that the company's injection production line has passed the GMP re-certification of the EU Croatian Drug and Medical device Administration and obtained the GMP certificate, indicating that the company's injection products continue to have EU market access qualifications. This certification involves the company's product is Atosiban Acetate injection. Atosiban is a competitive antagonist of oxytocin receptor, which is used to postpone the upcoming preterm labor with good clinical effect and few side effects.